

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES, NOR IS IT A PROSPECTUS ANNOUNCEMENT. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, OUTSIDE INDIA. INITIAL PUBLIC OFFERING OF EQUITY SHARES ON THE MAIN BOARD OF THE STOCK EXCHANGES IN COMPLIANCE WITH CHAPTER II OF THE 'SECURITIES AND EXCHANGE BOARD OF INDIA (ISSUE OF CAPITAL AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2018, AS AMENDED.



(Please scan the QR Code to view this Addendum)

PUBLIC ANNOUNCEMENT

With Chemistry, We Can...



ALLCHEM LIFESCIENCE LIMITED

Our Company was originally incorporated as 'Allchem Lifescience Private Limited', at Ahmedabad as a private limited company under the provisions of Companies Act, 2013 and received a certificate of incorporation issued by the RoC on January 12, 2017. Thereafter, pursuant to a special resolution passed by the shareholders of our Company in their meeting on September 13, 2024, the name of our Company was changed from 'Allchem Lifescience Private Limited' to 'Allchem Lifescience Limited', and a fresh certificate of incorporation dated October 28, 2024, was issued to our Company by the RoC. For details of changes in the name and registered office of our Company, see 'History and Certain Corporate Matters' on page 227 of the Draft Red Herring Prospectus dated March 13, 2025 ("DRHP" or "the Draft Red Herring Prospectus").

Registered and Corporate Office: Block No. 1088/B/P,1088-A, Lamdapura Road, Village Manjusar, Tal-Savli, Vadodara, Gujarat - 391775, India.

Contact Person: Jigardan Gadhvi, Company Secretary and Compliance Officer; Tel: +91-9574722211

E-mail: investor@allchemlifescience.com; Website: www.allchemlifescience.com

Corporate Identification Number: U24299GJ2017PLC095094

NOTICE TO INVESTORS: ADDENDUM TO THE DRAFT RED HERRING PROSPECTUS DATED MARCH 13, 2025 (ADDENDUM)

OUR PROMOTERS: BIPIN PATEL, KANTILAL RAMANLAL PATEL, MANISHA BIPIN PATEL AND ADITI PATEL

DISCLAIMER: AS ON DATE, OUR COMPANY IS NOT ASSOCIATED WITH ALKEM LABORATORIES LIMITED IN ANY MANNER

INITIAL PUBLIC OFFER OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH (EQUITY SHARES) OF ALLCHEM LIFESCIENCE LIMITED (COMPANY) FOR CASH AT A PRICE OF ₹ [●] PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹ [●] PER EQUITY SHARE) (OFFER PRICE) AGGREGATING UP TO ₹ [●] MILLION (OFFER) COMPRISING A FRESH ISSUE OF UP TO [●] EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING UP TO ₹ 1,900.00 MILLION BY OUR COMPANY (FRESH ISSUE) AND AN OFFER FOR SALE OF UP TO 7,155,000 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING UP TO ₹ [●] MILLION BY THE PROMOTER SELLING SHAREHOLDERS (OFFER FOR SALE) COMPRISING UP TO 3,577,500 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING UP TO ₹ [●] MILLION BY KANTILAL RAMANLAL PATEL, AND UP TO 3,577,500 EQUITY SHARES OF FACE VALUE OF ₹ 10 EACH AGGREGATING UP TO ₹ [●] MILLION BY MANISHA BIPIN PATEL, (COLLECTIVELY, THE PROMOTER SELLING SHAREHOLDERS, AND SUCH EQUITY SHARES, THE OFFERED SHARES), THE OFFER SHALL CONSTITUTE [●] % OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY.

This Addendum is in reference to the Draft Red Herring Prospectus filed with SEBI and the Stock Exchanges in relation to the Offer. In this regard, potential Bidders should note the following modifications to the disclosure in the Draft Red Herring Prospectus.

Subsequent to the filing of the Draft Red Herring Prospectus, Alkem Laboratories Limited has filed a suit against our Company before the Hon'ble High Court of Delhi on April 23, 2025 alleging *inter alia* infringement and passing off of trademark of Alkem Laboratories Limited with respect to the use of the mark / name 'Allchem'. Accordingly, the following modifications to the Draft Red Herring Prospectus should be noted:

1. Inclusion of a new risk factor in the section titled "Risk Factors" on page 27 of the Draft Red Herring Prospectus:

"...**Alkem Laboratories Limited has filed a suit against our Company before the Hon'ble High Court of Delhi alleging inter alia infringement and passing off of trademark of Alkem Laboratories Limited with respect to the use of the mark / name 'Allchem' / 'ALLCHEM' by our Company and has inter alia sought a (i) permanent injunction on the use of said mark / name; (ii) permanent injunction against the Offer under the said mark / name; (iii) decree for damages for an amount of ₹20.00 million for alleged loss of goodwill and reputation suffered by Alkem Laboratories Limited; and (iv) decree rendition of accounts of profit earned by our Company by use of the mark / name. If any adverse order is passed in the matter, then our Company will not be able to sell our products under the said mark / name which may have an adverse impact on our business, prospects, reputation, goodwill, and our results of operations.**

Alkem Laboratories Limited (**Alkem Laboratories**) has filed a suit (bearing number CS(COMM) 372/2025) before the Hon'ble High Court of Delhi on April 23, 2025 alleging *inter alia* infringement and passing off of trademark of Alkem Laboratories with respect to the use of the mark / name 'Allchem' / 'ALLCHEM' by our Company and seeking certain reliefs *inter alia* (i) permanent injunction on use by our Company of the said mark / name or any other alleged deceptively similar mark to Alkem Laboratories' mark "ALKEM," amounting to alleged infringement of Alkem Laboratories' registered trademarks; (ii) permanent injunction on our Company from undertaking an initial public offering under the said mark / name of our Company or any other alleged deceptively similar mark to Alkem Laboratories' mark "ALKEM"; (iii) permanent injunction on alleged passing off of the goods of our Company as those of Alkem Laboratories, alleged dilution of goodwill and reputation of Alkem Laboratories, and alleged unfair competition; (iv) decree of delivery up of the goods bearing the said mark, and rendition of accounts of profit earned by our Company by use of the said mark; and (v) decree for damages for an amount of ₹20.00 million for alleged loss of goodwill and reputation suffered by Alkem Laboratories (**Suit**).

The Hon'ble High Court of Delhi, has passed an order dated April 24, 2025 *inter alia* (i) directing the parties to mediation before the Delhi High Court Mediation and Conciliation Centre on April 28, 2025; (ii) recording our Company's submission that in all future communications in relation to the Offer including the advertisements to be taken out by our Company in this regard, our Company shall put a disclaimer that as on date, our Company is not associated with Alkem Laboratories in any manner; (iii) allowed time to the parties to file their respective pleadings in the matter; and (iv) has listed the matter before the Hon'ble High Court of Delhi on July 9, 2025. Pursuant to the order of the Hon'ble High Court of Delhi, our Company and Alkem Laboratories have participated in mediation sessions before the Delhi High Court Mediation and Conciliation Centre on various dates, and the next mediation session is scheduled on June 11, 2025. The matter is currently pending. Also, see 'Outstanding Litigation and Other Material Development - Litigations involving our Company - Litigation initiated by our Company - Material outstanding litigations' at page [●] of the DRHP.

If any adverse order is passed in the matter, then our Company will not be able to sell our products under the said mark / name which may have an adverse impact on our business, prospects, reputation, goodwill, and our results of operations...."

2. Inclusion of summary of litigation in the section titled 'Outstanding Litigation and Other Material Development - Litigations involving our Company - Litigation initiated by our Company - Material outstanding litigations' on page 400 of the DRHP:

"...Material outstanding litigations

"...Alkem Laboratories has filed a suit (bearing number CS(COMM) 372/2025) before the Hon'ble High Court of Delhi on April 23, 2025 alleging *inter alia* infringement and passing off of trademark of Alkem Laboratories with respect to the use of the mark / name 'Allchem' / 'ALLCHEM' by our Company and seeking certain reliefs *inter alia* (i) permanent injunction on use by our Company of the said mark / name or any other alleged deceptively similar mark to Alkem Laboratories' mark "ALKEM," amounting to alleged infringement of Alkem Laboratories' registered trademarks; (ii) permanent injunction on our Company from undertaking an initial public offering under the said mark / name of our Company or any other alleged deceptively similar mark to Alkem Laboratories' mark "ALKEM"; (iii) permanent injunction on alleged passing off of the goods of our Company as those of Alkem Laboratories, alleged dilution of goodwill and reputation of Alkem Laboratories, and alleged unfair competition; (iv) decree of delivery up of the goods bearing the said mark, and rendition of accounts of profit earned by our Company by use of the said mark; and (v) decree for damages for an amount of ₹20.00 million for alleged loss of goodwill and reputation suffered by Alkem Laboratories (**Suit**). The Suit, along with Alkem Laboratories' applications (bearing number I.A. 10289-10292/2025) were listed for hearing before the Hon'ble High Court of Delhi on April 24, 2025.

The Hon'ble High Court of Delhi, has passed an order dated April 24, 2025 *inter alia* (i) directing the parties to mediation before the Delhi High Court Mediation and Conciliation Centre on April 28, 2025; (ii) recording our Company's submission that in all future communications in relation to the Offer including the advertisements to be taken out by our Company in this regard, our Company shall put a disclaimer that as on date, our Company is not associated with Alkem Laboratories in any manner; (iii) allowed time to the parties to file their respective pleadings in the matter; and (iv) has listed the matter before the Hon'ble High Court of Delhi on July 9, 2025. Pursuant to the order of the Hon'ble High Court of Delhi, our Company and Alkem Laboratories have participated in mediation sessions before the Delhi High Court Mediation and Conciliation Centre on various dates, and the next mediation session is scheduled on June 11, 2025. The matter is currently pending...."

This Addendum should be read in conjunction with the Draft Red Herring Prospectus. The information in this Addendum supplements and updates the information in the Draft Red Herring Prospectus. However, this Addendum does not purport to, nor does it, reflect all the changes that have occurred from the date of filing of the Draft Red Herring Prospectus and the date of this Addendum, except to the extent of the modifications included in the Addendum. Please note that the information included in the Draft Red Herring Prospectus will be suitably updated, including to the extent updated by way of this Addendum, as may be applicable, in the Red Herring Prospectus and Prospectus. Investors should not rely on the Draft Red Herring Prospectus or this Addendum for any investment decision, and should read the Red Herring Prospectus, as and when it is filed with the ROC, SEBI and the Stock Exchanges, before making an investment decision with respect to the Offer.

Unless otherwise specified, all capitalized terms used herein shall have the same meaning ascribed to such terms in the DRHP. For further details, please refer to the DRHP.

This Addendum which has been filed with SEBI shall be made public for comments for a period of at least 21 days from the date of publication of this Addendum and shall be available on the website of SEBI at www.sebi.gov.in, the website of Stock Exchanges at www.nseindia.com and www.bseindia.com, the website of our Company at www.allchemlifescience.com and the website of Book Running Lead Manager, i.e., Emkay Global Financial Services Limited at www.emkayglobal.com.

BOOK RUNNING LEAD MANAGER	REGISTRAR TO THE OFFER
 Your success is our success	 MUFG Intime
Emkay Global Financial Services Limited 7 th Floor, The Ruby, Senapati Bapat Marg, Dadar (West), Mumbai - 400 028, Maharashtra, India Tel: +91 22 6612 1212 E-mail: allchem.ipo@emkayglobal.com Website: www.emkayglobal.com Investor grievance e-mail: ibg@emkayglobal.com Contact person: Pranav Nagar / Pooja Sarvankar SEBI Registration Number: INM000011229	MUFG Intime India Private Limited (formerly Link intime India Private Limited) C-101, 247 Park, 1 st Floor, L B S Marg, Vikhroli (West), Mumbai - 400 083, Maharashtra, India. Tel: +91 8108114949 E-mail: allchemlifescience.ipo@in.mprms.mufg.com Website: www.linkintime.co.in Investor grievance e-mail: allchemlifescience.ipo@in.mprms.mufg.com Contact Person: Shanti Gopalkrishnan SEBI Registration Number: INR000004058

For ALLCHEM LIFESCIENCE LIMITED

On behalf of the Board of Directors

Sd/-

Place: Vadodara, Gujarat

Date: June 11, 2025

Jigardan Gadhvi

Company Secretary and Compliance Officer

ALLCHEM LIFESCIENCE LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the DRHP with SEBI and the Stock Exchanges on March 13, 2025. The DRHP shall be available on the website of SEBI at www.sebi.gov.in, as well as on the websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, on the website of our Company at www.allchemlifescience.com and the website of the BRLM, i.e. Emkay Global Financial Services Limited at www.emkayglobal.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" on page 27 of the DRHP. Potential Bidders should not rely on the DRHP filed with SEBI and the Stock Exchanges for making any investment decision.

This announcement does not constitute an invitation or offer of securities for sale in any jurisdiction. The Equity Shares offered in the Issue have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended ("U.S. Securities Act") or any state securities law in the United States, and unless so registered and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in accordance with any applicable U.S. applicable state securities laws. Accordingly, the Equity Shares are only being offered and sold (a) in the United States only to "qualified institutional buyers" (as defined in Rule 144A under the U.S. Securities Act) in transactions exempt from, or not subject to the registration requirements of the U.S. Securities Act and (b) outside the United States in "offshore transactions" in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales occur. There will be no offering of securities in the United States.